Back to Journals » OncoTargets and Therapy » Volume 12

Prognostic implications of MYBL2 in resected Chinese gastric adenocarcinoma patients

Authors Jia YX, Gao YP, Li J, Chang ZW, Yan J, Qin YR

Received 26 September 2018

Accepted for publication 21 December 2018

Published 11 February 2019 Volume 2019:12 Pages 1129—1135

DOI https://doi.org/10.2147/OTT.S188820

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Andrew Yee

Peer reviewer comments 3

Editor who approved publication: Dr William Cho


Yongxu Jia,* Yaping Gao,* Jing Li,* Zhiwei Chang, Jie Yan, Yanru Qin

Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, Henan Province, People’s Republic of China

*These authors contributed equally to this work

Background and aim: Gastric cancer (GC), a malignant tumor worldwide, is mostly diagnosed at an advanced stage. We selected the oncogene encoding transcription factors MYBL2 to investigate the connection between MYBL2 expression and GC prognosis.
Materials and methods: MYBL2 mRNA and protein expression were measured by real-time PCR and immunohistochemistry, respectively. The relationship between MYBL2 protein expression and survival time was estimated by the Kaplan–Meier analysis. Cox proportional hazards model was used to evaluate the prognostic impact of MYBL2 expression.
Results: The overexpression of MYBL2 was related to tumor cell differentiation, Lauren type, and metastasis of lymph nodes (P<0.05). In the MYBL2 overexpression group, the median disease free survival was even poorer (P=0.000) and it comes to median overall survival (P=0.000). The study showed that MYBL2 expression was an independent hazard for disease free survival (P=0.004).
Conclusion: The results of this study suggest that MYBL2 could indicate a promisingly prognostic biomarker for GC patients.

Keywords: MYBL2, gastric cancer, prognosis, upregulation, survival analysis


Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]